Summary. A competitive production method using the biotransformation of 4-butyrobetaine to enantiomerically pure L-carnitine was developed and scaled-up by Lonza. The process produces L-carnitine in 99.5% yield, and >99.9% enantiomeric excess (ee). Continuous and discontinuous processes were developed but the fed-batch process was found to be economically the most favourable process mode.